PAVmed and Lucid Diagnostics Welcome New Full-Time Investor Relations Team
12 Januar 2022 - 02:25PM
Business Wire
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a
diversified commercial-stage medical technology company, and its
majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq:
LUCD) (“Lucid”), a commercial-stage cancer prevention
diagnostics company, today announced they have launched a new,
full-time investor relations team to serve both companies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220112005563/en/
Adrian K. Miller has been appointed Vice President, Investor
Relations, with broad strategic responsibilities across all aspects
of investor communications, as well as a specific focus on
institutional investors. D.A. Wallace has been appointed Director,
Retail Investor Relations, working closely with Mr. Miller.
“PAVmed and Lucid have always been committed to transparent and
substantive communications with our shareholders through periodic
public communications, as well as extensive direct interactions,”
said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive
Officer and Lucid’s Chairman and Chief Executive Officer. “We are
now adding the necessary resources to assure that, during our
current rapid growth phase, we continue to serve our shareholders’
needs and significantly expand our capacity to communicate to the
broader investor community. Mr. Miller is a seasoned Wall Street
veteran who brings extensive experience and strong relationships to
this leadership role, and I look forward to working closely with
him and the entire team to live up to these commitments.”
Adrian Miller has over 20 years of experience in communications
across the capital markets landscape. He most recently served as
Director of Investor Relations and Chief Market Strategist at
Concise Capital, where he was responsible for interacting with
existing and potential investors to communicate investment
strategy, cultivate a presence for the firm with reporters across
financial media outlets, and distribute commentary to the
investment media to help build the firm’s brand. Prior to that, Mr.
Miller served as Chief Operating Officer of LM Capital Solutions,
LLC, Director of Global Fixed Income Strategy at GMP Securities,
and Director of Convertible and Credit Strategy at Citigroup. Mr.
Miller received his undergraduate degree in Accounting and Finance
from Widener University and serves as an adjunct professor at
Fairleigh Dickinson University in the areas of finance, economics,
and investing.
D. A. Wallace brings over 20 years of institutional and retail
investor relations experience, at companies including Home Depot
and Cox Communications, First Data, ResCare, and The National
Association of Investors Corp. Mr. Wallace is a former stockbroker
and investment bank analyst. He received his MBA from Keller
Graduate School of Management.
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology
company operating in the medical device, diagnostics, and digital
health sectors. Its major subsidiary, Lucid Diagnostics Inc.
(Nasdaq: LUCD), markets the EsoGuard® Esophageal DNA Test and
EsoCheck® Esophageal Cell Collection Device—the first and only
commercial tools for widespread early detection of esophageal
precancer to prevent esophageal cancer deaths. Another major
subsidiary, Veris Health Inc., is a digital health company
developing the first intelligent implantable vascular access port
with biologic sensors and wireless communication to improve
personalized cancer care through remote patient monitoring.
PAVmed’s CarpX® Minimally Invasive Device for Carpal Tunnel
Syndrome is currently in limited commercial release. The product
pipeline also includes the EsoCure™ Esophageal Ablation Device with
Caldus™ Technology, which complements EsoGuard and EsoCheck, the
NextFlo™ Intravenous Infusion Set, the PortIO™ Implantable
Intraosseous Vascular Access Device, novel pediatric ear tubes,
mechanical circulatory support technology and glucose monitoring.
For more information, please visit www.pavmed.com, follow us on
Twitter, connect with us on LinkedIn, and watch our videos on
YouTube.
About Lucid Diagnostics
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage,
cancer prevention medical diagnostics company, and subsidiary of
PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of
patients with gastroesophageal disease (GERD), also known as
chronic heartburn, who are at risk of developing esophageal
precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test,
performed on samples collected in a rapid, noninvasive office
procedure with its EsoCheck® Esophageal Cell Collection Device, is
the first and only commercially available diagnostic test capable
of serving as a widespread screening tool to prevent cancer and
cancer deaths through early detection of esophageal precancer in
at-risk GERD patients. EsoGuard is commercialized in the U.S. as a
Laboratory Developed Test (LDT). EsoCheck is commercialized in the
U.S. as a 510(k)-cleared esophageal cell collection device.
EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device
designation and is the subject of two large, actively enrolling,
international multicenter clinical trials to support FDA PMA
approval. Lucid is building a network of Lucid Test Centers where
at-risk GERD patients can undergo the EsoCheck procedure for
EsoGuard testing.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of PAVmed’s and Lucid’s management, are subject to
risks and uncertainties, which could cause actual results to differ
from the forward-looking statements. Risks and uncertainties that
may cause such differences include, among other things, volatility
in the price of PAVmed’s and Lucid’s common stock; PAVmed’s Series
W and Series Z warrants; general economic and market conditions;
the uncertainties inherent in research and development, including
the cost and time required to advance PAVmed’s and Lucid’s products
to regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from PAVmed’s and Lucid’s
clinical and preclinical studies; whether and when PAVmed’s and
Lucid’s products are cleared by regulatory authorities; market
acceptance of PAVmed’s and Lucid’s products once cleared and
commercialized; PAVmed’s and Lucid’s ability to raise additional
funding as needed; and other competitive developments. In addition,
PAVmed and Lucid have been monitoring the COVID-19 pandemic and the
pandemic’s impact on PAVmed’s and Lucid’s businesses. PAVmed and
Lucid expect the significance of the COVID-19 pandemic, including
the extent of its effect on its financial and operational results,
to be dictated by, among other things, the success f efforts to
contain the pandemic and the impact of such efforts on PAVmed’s and
Lucid’s businesses. These factors are difficult or impossible to
predict accurately and many of them are beyond PAVmed’s and Lucid’s
control. In addition, new risks and uncertainties may arise from
time to time and are difficult to predict. For a further list and
description of these and other important risks and uncertainties
that may affect PAVmed’s and Lucid’s future operations, see Part I,
Item IA, “Risk Factors,” in PAVmed’s most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, as the
same may be updated in Part II, Item 1A, “Risk Factors” in any
Quarterly Report on Form 10-Q filed by PAVmed after its most recent
Annual Report and Lucid’s Registration Statement No. 333-259721
filed with the Securities and Exchange Commission. PAVmed and Lucid
disclaim any intention or obligation to publicly update or revise
any forward-looking statement to reflect any change in its
expectations or in events, conditions, or circumstances on which
those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220112005563/en/
Investors Adrian Miller PAVmed and
Lucid Diagnostics (201) 803-0388 AKM@pavmed.com
Media Kristi Bruno
LaVoieHealthScience (617) 865-3940
PAVmed@lavoiehealthscience.com
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
Von Mär 2023 bis Mär 2024